EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma

Jinbo Huang iD, Jiajie Su, Haiyu Wang, Jiayi Chen, Yuan Tian, Jun Zhang, Tingting Feng, Longjiang Di, Xiaopeng Lu, Hao Sheng, Qian Zhu iD, Xinyun Chen und 9 weitere

Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17319-17349

DOI: 10.1021/acs.jmedchem.4c01223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.09.2024. Verfasst von Jinbo Huang und 20 weiteren Autor:innen. Beteiligte Einrichtung: International Cancer Center, Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Marshall Laboratory of Biomedical Engineeri…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sirtuins, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, National Key Research and Development Program of China, Anhui Normal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirtuin 6 (SIRT6), a member of the SIRT family, plays essential roles in the regulation of metabolism, inflammation, aging, DNA repair, and cancer development, making it a promising anticancer drug target. Herein, we present our use of proteolysis-targeting chimera (PROTAC) technology to formulate a series of highly potent and selective SIRT6 degraders. One of the degraders, SZU-B6, induced the near-complete degradation of SIRT6 in both SK-HEP-1 and Huh-7 cell lines and more potently inhibited hepatocellular carcinoma (HCC) cell proliferation than the parental inhibitors. In preliminary mechanistic studies, SZU-B6 hampered DNA damage repair, promoting the cellular radiosensitization of cancer cells. Our SIRT6 degrader SZU-B6 displayed promising antitumor activity, particularly when combined with the well-known kinase inhibitor sorafenib or irradiation in an SK-HEP-1 xenograft mouse model. Our results suggest that these PROTACs might constitute a potent therapeutic strategy for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularSirtuinsLiver NeoplasmsAntineoplastic AgentsProteolysisCell ProliferationHumansAnimalsMiceCell Line, TumorMice, NudeXenograft Model Antitumor AssaysDrug DiscoveryStructure-Activity Relationship

Substanzen

SirtuinsSIRT6 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • International Cancer Center, Guangdong Key Laboratory of Genome Instability and Human Disease Prevention, Marshall Laboratory of Biomedical Engineering, Department of Biochemistry and Molecular Biology, Health Science C…
  • Shenzhen University School of Pharmacy, Shenzhen University Medical School, Shenzhen 518055, China.
  • National Engineering Research Centrer for Biotechnology, Shenzhen 518055, China.
  • School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
  • School of Basic Medical Sciences, Wannan Medical College, Wuhu, Anhui 241002, China.
  • Department of Urology, Peking University First Hospital, Beijing 100035, China.

ORCID-Profile: Jinbo Huang, Qian Zhu, Wei-Guo Zhu

Förderung

  • Guangdong Provincial Department of Science and Technology
  • National Key Research and Development Program of China
  • Anhui Normal University
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • National Natural Science Foundation of China
  • Shenzhen University
  • Shenzhen Medical Research Fund

Zitieren

APA

Huang, J., Su, J., Wang, H., Chen, J., Tian, Y., Zhang, J., Feng, T., Di, L., Lu, X., Sheng, H., Zhu, Q., Chen, X., Wang, J., He, X., Yerkinkazhina, Y., Xie, Z., Shu, Y., Kang, T., Tang, H., …, & Zhu, W. G. (2024). Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma. Journal of Medicinal Chemistry, 67(19), 17319-17349. https://doi.org/10.1021/acs.jmedchem.4c01223

Vancouver

Huang J, Su J, Wang H, Chen J, Tian Y, Zhang J, et al. Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2024;67(19):17319-17349. doi:10.1021/acs.jmedchem.4c01223

BibTeX
@article{Huang2024,
  author = {Huang, Jinbo and Su, Jiajie and Wang, Haiyu and Chen, Jiayi and Tian, Yuan and Zhang, Jun and Feng, Tingting and Di, Longjiang and Lu, Xiaopeng and Sheng, Hao and Zhu, Qian and Chen, Xinyun and Wang, Jingchao and He, Xingkai and Yerkinkazhina, Yerkezhan and Xie, Zhongyi and Shu, Yuxin and Kang, Tianshu and Tang, Huangqi and Qian, Jinqin and Zhu, Wei-Guo},
  title = {Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {19},
  pages = {17319--17349},
  doi = {10.1021/acs.jmedchem.4c01223}
}
Kostenlos starten →